Data-driven design and screening of novel Klebsiella pneumoniae carbapenemase-2 β-lactamase inhibitors using a generative CLM
RSC Advances · 2026 · 16 (31) · 28845-28856
DOI: 10.1039/d6ra02379g ↗Kurz gefasst
Fachartikel in der Zeitschrift RSC Advances, 2026. Verfasst von Syeda Sumayya Tariq und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi Karach…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Using generative chemical language modeling (CLM) for the design and discovery of novel KPC-2 Inhibitors targeting Klebsiella pneumonia .
Autor:innen und Institutionen
- Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi Karachi-75270 Pakistan mriazuddin@iccs.edu.
- School of Electronic Engineering and Computer Science, Queen Mary University of London E1 4NS UK.
- Western Caspian University Baku Azerbaijan.
ORCID-Profile: Reaz Uddin
Zitieren
APA
Tariq, S. S., Haleem, M. S., & Uddin, R. (2026). Data-driven design and screening of novel Klebsiella pneumoniae carbapenemase-2 β-lactamase inhibitors using a generative CLM. RSC Advances, 16(31), 28845-28856. https://doi.org/10.1039/d6ra02379g
Vancouver
Tariq SS, Haleem MS, Uddin R. Data-driven design and screening of novel Klebsiella pneumoniae carbapenemase-2 β-lactamase inhibitors using a generative CLM. RSC Advances. 2026;16(31):28845-28856. doi:10.1039/d6ra02379g
BibTeX
@article{Tariq2026,
author = {Tariq, Syeda Sumayya and Haleem, Muhammad Salman and Uddin, Reaz},
title = {Data-driven design and screening of novel Klebsiella pneumoniae carbapenemase-2 β-lactamase inhibitors using a generative CLM},
journal = {RSC Advances},
year = {2026},
volume = {16},
number = {31},
pages = {28845--28856},
doi = {10.1039/d6ra02379g}
}
EUVIMED